{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:58:13Z","timestamp":1793210293414,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008965.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000}}],"reference-count":305,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008965.pub4","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T05:50:27Z","timestamp":1397109027000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":227,"title":["Neuraminidase inhibitors for preventing and treating influenza in adults and children"],"prefix":"10.1002","volume":"2018","author":[{"given":"Tom","family":"Jefferson","sequence":"first","affiliation":[{"name":"University of Oxford; Centre for Evidence Based Medicine; Oxford UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Jones","sequence":"additional","affiliation":[{"name":"The University of Queensland; School of Public Health; Public Health Building Herston Road Brisbane Queensland Australia 4006"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Doshi","sequence":"additional","affiliation":[{"name":"University of Maryland School of Pharmacy; Department of Pharmaceutical Health Services Research; 220 Arch Street, 12th floor, Room 01-228 Baltimore Maryland USA 21201"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris B","family":"Del Mar","sequence":"additional","affiliation":[{"name":"Bond University; Centre for Research in Evidence-Based Practice (CREBP); University Drive Gold Coast Queensland Australia 4229"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokuro","family":"Hama","sequence":"additional","affiliation":[{"name":"Japan Institute of Pharmacovigilance; 902 Ueshio 3-2-17 Osaka Japan 543-0002"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Washington; Department of Family Medicine; Box 354696 Seattle WA USA 98195-4696"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Spencer","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Oxford Oxfordshire UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igho J","family":"Onakpoya","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Oxford Oxfordshire UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal R","family":"Mahtani","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Oxford Oxfordshire UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nunan","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Oxford Oxfordshire UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Howick","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Oxford Oxfordshire UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J","family":"Heneghan","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Oxford Oxfordshire UK OX2 6GG"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,10]]},"reference":[{"key":"10.1002\/14651858.CD008965.pub4-BIB0001|cit1","unstructured":"GSK Investigation of the efficacy of GG167 (zanamivir) in the treatment of influenza\u00a0viral infections (late Phase II study: dose comparison study) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0002|cit2","unstructured":"GSK Investigation of the efficacy of CG167 in the treatment of influenza viral infections (phase II study) (Protocol NoJNAI-01). Double blind, double dummy, randomized, placebo controlled, parallel group, multicenter study to investigate safety and route of administration of CG167 when inhaled, CG167 10 mg, or the combination of inhaled CG167 10 mg plus intranasal CG167 6.4 mg, administered twice daily for 5 days in the treatment of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0003|cit3","unstructured":"GSK A multicenter two way layout randomized placebo-controlled double-blind trial parallel group comparative trial on the efficacy and safety of GG167 (zanamivir) 10 mg twice a day and 20 mg twice a day in the treatment of influenza type A and type B infections (late Phase II study: dose comparison study) (Protocol No. JNAI-04) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0004|cit4","unstructured":"GSK A multicenter two way layout randomized placebo-controlled double-blind trial parallel group comparative trial on the efficacy and safety of GG167 (zanamivir) 10 mg twice a day and 20 mg twice a day\u00a0in the treatment of influenza type A and type B infections (late Phase II study: dose comparison study) (Protocol No.JNAI-07) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0005|cit5","unstructured":"No authors listed A randomized, placebo-controlled, multicenter study of oseltamivir (Ro 64-0796) in the treatment of influenza in Japanese subjects (Translation of summary Japanese report - of 29 pages) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0006|cit6","unstructured":"No authors listed Phase 3 study for prophylaxis of influenza with Ro64-0796 (15 page summary from Japanese) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0007|cit7","unstructured":"McGarty T A randomized, double-blind, placebo-controlled, multicenter study of efficacy based on the time to treatment of influenza infection with the neuraminidase inhibitor Ro 64-0796 (also known as GS 4104) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0008|cit8","unstructured":"No authors listed A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate in the treatment of influenza infection in China Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0009|cit9","unstructured":"No authors listed A double-blind, randomized, placebo-controlled, parallel group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of influenza in patients 12 years or over diagnosed with asthma or chronic obstructive pulmonary disease Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0010|cit10","unstructured":"Alfors S Keene O Grice R Hammond J Hendricks V Martin N A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12 Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0011|cit11","unstructured":"Hunter S Reilly L Sharp S West M Alfors S Hammond J A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0012|cit12","unstructured":"No authors listed A randomised, double-blind, placebo-controlled study to evaluate the impact of inhaled zanamivir treatment on workplace attendance due to influenza A and B infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0013|cit13","unstructured":"No authors listed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in subjects aged over 65 years Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0014|cit14","unstructured":"No authors listed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0015|cit15","unstructured":"No authors listed A double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd. via Diskhaler), for 5 days, in high risk patients with symptomatic influenza A and \/ or B infection Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0016|cit16","unstructured":"No authors listed A double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd via Diskhaler), for 5 days, in children aged 5 to 12 years with symptomatic influenza A and \/ or B infection Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0017|cit17","unstructured":"No authors listed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within households Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0018|cit18","unstructured":"No authors listed A double-blind, randomized, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community-dwelling high-risk populations Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0019|cit19","unstructured":"No authors listed A double-blind, randomized, placebo-controlled, multicenter, parallel-group study to investigate the efficacy and safety of zanamivir administered twice or four times a day for the treatment of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0020|cit20","unstructured":"No authors listed A double-blind, randomised, placebo-controlled, multicentre, parallel-group study to demonstrate the efficacy and safety of zanamivir in the prevention and\/or progression of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0021|cit21","unstructured":"MacLeod A Gummer M Raniga K Hirst H Keene O Ossi M A double-blind, randomised, placebo-controlled multi-centre study to investigate the efficacy and safety of inhaled and intranasal zanamivir in the treatment of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0022|cit22","unstructured":"No authors listed A double-blind, randomised, placebo-controlled multicentre study to investigate the efficacy and safety of zanamivir therapy in the prevention of progression of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0023|cit23","unstructured":"Elliott M Flack N Keene O Szymborski P Vega R (PharmaResearch Inc) A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0024|cit24","unstructured":"No authors listed A double-blind, randomized, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg administered once a day compared to the standard of care in controlling nursing home influenza outbreaks Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0025|cit25","unstructured":"No authors listed A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0026|cit26","unstructured":"Elliott M Hunter S Flack N Crisp A Szymborski P Vega R A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0027|cit27","unstructured":"Leong J Brennan J Gummer M Keene O Wightman K A double-blind, randomised, placebo-controlled, parallel-group, multi-centre study to investigate the efficacy and safety of inhaled plus intranasal zanamivir in the treatment of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0028|cit28","unstructured":"No authors listed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir in preventing progression of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0029|cit29","unstructured":"Perich R Solterbeck A Keene O Leong J Raniga K MacLeod A A double-blind, randomised, placebo-controlled, parallel-group, multi-centre study to investigate the efficacy and safety of inhaled and inhaled plus intranasal zanamivir in the treatment of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0030|cit30","unstructured":"Campion K Gummer M Keene O A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0031|cit31","unstructured":"Man CY Keene ON Challoner T (Challoner Associates) A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0032|cit32","unstructured":"No authors listed A double-blind, randomized, stratified, placebo-controlled study of oseltamivir in the treatment of influenza in children with asthma Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0033|cit33","unstructured":"No authors listed A trial to investigate efficacy to reduce development of influenza symptoms in influenza infected patients treated with GG167 (protocol number PE-01 phase II clinical trial).\u00a0A double-blind double-dummy, randomized, placebo-controlled, parallel group, multicenter study to investigate the efficacy reducing development of influenza symptoms and, safety and rout of administration of GG 157 when orally inhaled GG 167 10 mg, 6.4 mg nebulized intranasally or the combination of inhaled GG167 10 mg plus intranasal GG167 6.4 mg was administered twice day for 5 days in the treatment of influenza A and B viral infections Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0034|cit34","unstructured":"Dorkings J Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0035|cit35","unstructured":"Dorkings J Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0036|cit36","unstructured":"No authors listed Efficacy of Ro 64-0796 when used as chemoprophylaxis against natural influenza infection Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0037|cit37","unstructured":"Grosse M A multi-center, randomized, double-blind, placebo-controlled, parallel group study of oseltamivir treatment in elderly patients with influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0038|cit38","unstructured":"No authors listed A double-blind randomised placebo controlled study of Ro 64-0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during influenza season Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0039|cit39","unstructured":"Dorkings J A double-blind, stratified, randomized, placebo controlled study of Ro 64-0796 (GS4104) in the treatment of influenza infection in adults Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0040|cit40","unstructured":"No authors listed A double-blind, randomized, stratified, placebo-controlled study of Ro 64-0796 (also known as GS 4104) in the treatment of children with influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0041|cit41","unstructured":"Gerster T A double-blind, randomized, stratified, placebo-controlled study of oseltamivir phosphate (Ro 64-0796, also known as GS 4104) in the treatment of influenza in children with chronic asthma Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0042|cit42","unstructured":"No authors listed A double-blind randomised placebo controlled study of Ro 64-0796 (also known as GS4104) for the prevention of clinical influenza post exposure in families Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0043|cit43","unstructured":"McCarvil M A double-blind, stratified, randomised, placebo controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza in chronically ill adults Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0044|cit44","unstructured":"No authors listed A double-blind, randomized, stratified, placebo-controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza infection in elderly patients Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0045|cit45","unstructured":"No authors listed A double-blind, randomised, placebo-controlled study of Ro 64-0796 (also known as GS4104) used in elderly subjects for the prevention of clinical influenza during the influenza season Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0046|cit46","unstructured":"No authors listed A double-blind, randomised, stratified, placebo-controlled study of oseltamivir in the treatment of influenza infection in patients Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0047|cit47","unstructured":"A post-marketing surveillance to monitor the safety of RELENZA (zanamivir) administered in Korean subjects according to the prescribing information Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0048|cit48","unstructured":"An open label, single-dose, five-way crossover study examining relative oral bioavailability of zanamivir with bioenhancing excipients following direct release into mid-small intestine using gamma scintigraphy and the InteliSite Companion Capsule in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0049|cit49","unstructured":"An open-label, non-randomized, single-dose study to evaluate serum zanamivir pharmacokinetics following intravenous administration to human subjects with renal impairment compared to subjects without renal impairment Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0050|cit50","unstructured":"Special drug use investigation for Relenza (resistant appearance) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0051|cit51","unstructured":"Special drug use investigation for Relenza (efficacy) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0052|cit52","unstructured":"Drug use investigation for Relenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0053|cit53","unstructured":"Prophylactic efficacy of Relenza against influenza A and B Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0054|cit54","unstructured":"A randomized, placebo controlled, 3-way crossover study to investigate the safety, tolerability, and pharmacokinetics of repeat dose zanamivir\/placebo 10 mg administered twice daily for 5 days by a rotahaler compared to the diskhaler in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0055|cit55","unstructured":"An open-label, multi-center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0056|cit56","unstructured":"Collection of patients' background information Relenza\u00ae sentinel site monitoring program in Japan Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0057|cit57","unstructured":"A phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0058|cit58","unstructured":"A study of GG167 single blind, single administration - phase I Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0059|cit59","unstructured":"A study of GG167 single blind, single administration - phase I Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0060|cit60","unstructured":"A study of GG167 single blind, single administration - phase I Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0061|cit61","unstructured":"A study of GG167 single blind, single administration - phase I Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0062|cit62","unstructured":"(Zanamivir trial. Title unknown) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0063|cit63","unstructured":"A randomized open label study comparing the efficacy, safety, and tolerability of oral administration of amantadine and ribavirin with oseltamivir versus oseltamivir to influenza A virus infected immunocompromised subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0064|cit64","unstructured":"A single-center, open-label, single dose, exploratory study in Caucasian and Japanese healthy subjects to investigate the pharmacokinetics of oseltamivir and its metabolite in plasma and cerebrospinal fluid Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clinical Pharmacokinetics. 1999;36 Suppl 1:1-11. Not posted to GSK CTR","DOI":"10.2165\/00003088-199936001-00001"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Cass LM, Gunawardena KA, Macmahon MM, Bye A: Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respiratory Medicine 2000;94(2):166-73. Posted to GSK CTR","DOI":"10.1053\/rmed.1999.0718"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0067|cit67","unstructured":"A study to investigate the pharmacokinetics of GG167 in subjects with impaired renal function Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0068|cit68","unstructured":"(Zanamivir trial. Title unknown) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0069|cit69","unstructured":"(Zanamivir trial. Title unknown) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0070|cit70","unstructured":"Single ascending oral dose study of tolerability, safety and pharmacokinetics (including effect of food) of the neuraminidase inhibitor Ro 64-0796 in healthy male volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0071|cit71","unstructured":"Multiple oral dose study of the tolerability, safety and PK of the neuraminidase inhibitor Ro64-0796: direct PK comparison between Japanese and Caucasian subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0072|cit72","unstructured":"Phase II clinical study of oseltamivir phosphate (Ro64-0796) for the treatment of influenza in children Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0073|cit73","unstructured":"Post-marketing clinical study of oseltamivir phosphate on nighttime ECG in healthy adult male subjects Data on file 2008"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0074|cit74","unstructured":"Early administration of oral oseltamivir increases the benefits of influenza treatment Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0075|cit75","unstructured":"An observational study to assess the accuracy of diagnosis of influenza in community pharmacies Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0076|cit76","unstructured":"Phase IV study on Tamiflu\u00ae capsule 75 in the elderly aged 80 years or older (a single dose oral administration study for assessing pharmacokinetics in the elderly not infected with influenza virus) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0077|cit77","unstructured":"Impact of oseltamivir (Tamiflu \u00ae) in post-exposure prophylaxis influenza on mortality and morbidity in institutionalised elderly people. Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0078|cit78","unstructured":"Evaluation of combination therapy with oseltamivir and zanamivir versus monotherapy in the treatment of virologically confirmed influenza in primary care a randomised double blind controlled trial study Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0079|cit79","unstructured":"Efficacy and safety of combination therapies with oseltamivir & zanamivir or oseltamivir & amantadine versus oseltamivir monotherapy in the treatment of seasonal influenza A infection Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0080|cit80","unstructured":"An unblinded, comparative, randomized study of influenza A\/H1N1 2009 resistance in patients with standard and double dose oseltamivir treatment Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0081|cit81","unstructured":"Viral shedding\/resistance with double duration oseltamivir in infected patients (New Zealand) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0082|cit82","unstructured":"Viral shedding\/resistance with standard dose\/duration oseltamivir in infected patients (UK) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0083|cit83","unstructured":"A study of the relative oral bioavailability of the antiflu medicine oseltamivir (Tamiflu\u00ae) in patients in the intensive care unit Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0084|cit84","unstructured":"Viral shedding\/resistance with double dose oseltamivir in infected patients (Australia) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0085|cit85","unstructured":"Nasogastric administration of OP in infected patients with respiratory failure Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0086|cit86","unstructured":"Oseltamivir pharmacokinetics in morbid obesity Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0087|cit87","unstructured":"Open-label pharmacokinetic of oseltamivir in healthy obese Thai adult subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0088|cit88","unstructured":"A randomized, double-blinded controlled trial comparing high vs standard dose oseltamivir in severe, influenza infection in ICU. \"ROSII Study\" Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0089|cit89","unstructured":"Probing the functional expression of carboxyl esterase in preterm neonates using oseltamivir: a pragmatic observational study Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0090|cit90","unstructured":"Plasma levels of oseltamivir in H1N1 infected patients supported by extracorporeal membrane oxygenation: a single-centre cohort study Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0091|cit91","unstructured":"Effect of probenecid on the pharmacokinetics of oseltamivir Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0092|cit92","unstructured":"A prospective study to assess household transmission of influenza and emergence and transmissibility of drug resistance to oseltamivir following treatment of children with influenza A and B Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0093|cit93","unstructured":"High-dose versus standard-dose oseltamivir for the treatment of severe influenza and avian influenza: a phase II double-blind, randomized clinical trial Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0094|cit94","unstructured":"A study on higher-dose oseltamivir treatment's impact on viral clearance and clinical recovery in adults hospitalized with influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0095|cit95","unstructured":"A study of the pharmacology of oseltamivir (Tamiflu) in pregnancy Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0096|cit96","unstructured":"Pharmacokinetics of Tamiflu\u00ae (oseltamivir) in patients receiving extracorporeal membrane oxygenation (ECMO) and or continuous venovenous hemodialysis (CVVHD) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0097|cit97","unstructured":"Pharmacokinetics of oseltamivir in critically ill adult patients Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0098|cit98","unstructured":"Observational study on the pharmacokinetics of oseltamivir in the treatment of influenza during lactation Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0099|cit99","unstructured":"Phase I, open-label study to evaluate steady-state serum and pulmonary pharmacokinetics following intravenous administration of zanamivir in healthy adult subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0100|cit100","unstructured":"Phase 1, open-label study to evaluate potential pharmacokinetic interactions between orally-administered oseltamivir and intravenous zanamivir in healthy Thai adult subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0101|cit101","unstructured":"A double-blind, randomised, placebo-controlled study to evaluate the effect of inhaled zanamivir 10 mg od for 28 days on anti-haemagglutinin antibody production (HAI titre) following co-administration with Fluvirin\u2122 trivalent influenza vaccine in healthy adult subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0102|cit102","unstructured":"An open label, randomized evaluation of the direct measurement of zanamivir concentrations in respiratory secretions following a single dose inhalation of 10 mg RELENZA\u2122 via DISKHALER in health volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0103|cit103","unstructured":"An open-label, multi-center study of the patient instructional leaflet for RELENZA DISKHALER Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0104|cit104","unstructured":"Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0105|cit105","unstructured":"Pilot, cluster randomised, open, single centre, parallel group study to evaluate the efficacy and safety of zanamivir in controlling influenza outbreaks and preventing the development of resistant influenza cases in a high risk nursing home population, compared with usual care Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Cass LMR, Brown J, Pickford M, Fayinka S, Newman SP, Johansson CJ, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clinical Pharmacokinetics 1999 36:Suppl 1 (21-31). Not posted to GSK CTR","DOI":"10.2165\/00003088-199936001-00003"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0107|cit107","unstructured":"A study to evaluate the effect of repeat doses of GG167 dry powder on pulmonary function and bronchial hyper-responsiveness in asthmatic subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0108|cit108","unstructured":"A GG167 Pharmacokinetic Study to Select a Regimen for Prophylaxis Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0109|cit109","unstructured":"A phase I double-blind, placebo-controlled, dose-escalating study to evaluate the safety and tolerability of intravenous peramivir in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0110|cit110","unstructured":"An open-label, multiple dose, randomized, three-period crossover study in healthy volunteers to evaluate the effect of co-administration of amantadine 100 mg BID and oseltamivir 75 mg BID on the pharmacokinetic properties of amantadine and oseltamivir Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0111|cit111","unstructured":"TCAD vs. monotherapy for influenza A in immunocompromised patients Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0112|cit112","unstructured":"A phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous peramivir in hospitalized subjects with confirmed or suspected influenza infection Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0113|cit113","unstructured":"A pharmacokinetic\/pharmacodynamic and safety evaluation of investigational intravenous peramivir in children with influenza disease (CASG 117) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0114|cit114","unstructured":"(Oseltamivir trial. Title unknown) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0115|cit115","unstructured":"Multiple ascending oral dose study of the tolerability, safety and pharmacokinetics of the neuraminidase inhibitor Ro 64-0796 in healthy volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0116|cit116","unstructured":"Study of the PD and PK of the neuraminidase inhibitor Ro 64-0796 (GS4104) in the treatment of volunteers experimentally infected with human influenza B virus Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0117|cit117","unstructured":"An excretion balance and pharmacokinetic study of Ro 64-0796 after a single oral dose of 14C-labelled Ro 64-0796 and an intravenous dose of 14C-labelled Ro 64-0802 in healthy male subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0118|cit118","unstructured":"Study of the pharmacokinetics and absolute bioavailability of the neuraminidase inhibitor Ro 64-0796 Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0119|cit119","unstructured":"An open-label study of the effect of cimetidine and probenecid on the pharmacokinetics of Ro 64-0796\/GS4104 in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0120|cit120","unstructured":"An open-label bioequivalence and food effect study of the clinical trial and market formulations of Ro 64-0796 in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0121|cit121","unstructured":"No authors listed A palatability study of the neuraminidase inhibitor (Ro 64-0796), formulated as an oral formulation Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0122|cit122","unstructured":"No authors listed Study of the pharmacokinetics and pharmacodynamics of the neuraminidase inhibitor Ro 64-0796 (GS4104) in the prophylaxis of experimental infection of volunteers with the human influenza B virus Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0123|cit123","unstructured":"An open-label bioequivalence and food effect study of the clinical trial and market formulations of Ro 64-0796 in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0124|cit124","unstructured":"An open-label study of pharmacokinetics of Ro 64-0796\/GS4104 in children Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0125|cit125","unstructured":"Study of the pharmacodynamics of the neuraminidase inhibitor in the treatment of subjects experimentally infected with the human influenza B virus Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0126|cit126","unstructured":"Palatability testing of the neuraminidase inhibitor Ro 64-0796 in children. Research Report No. W-144154\/27 October 1999 Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0127|cit127","unstructured":"An open-label, two-way crossover pharmacokinetic drug interaction study of neuraminidase inhibitor Ro 64-0796\/GS4104 and amoxicillin in healthy volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0128|cit128","unstructured":"Palatability testing of the neuraminidase inhibitor Ro 64-0796 in children Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0129|cit129","unstructured":"A single center, open label, multiple dose oral oseltamivir suspension study in end-stage-renal disease (ESRD) patients on hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0130|cit130","unstructured":"An open-label, multiple dose, randomized, three-period crossover study in healthy subjects to evaluate the effect of co-administration of oseltamivir (RO0640796) 75 mg twice daily and rimantadine 100 mg twice daily on the pharmacokinetic properties of oseltamivir and rimantadine Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0131|cit131","unstructured":"A study of intravenous oseltamivir [Tamiflu] in infants with influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0132|cit132","unstructured":"A study of intravenous Tamiflu (oseltamivir) in children with influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0133|cit133","unstructured":"PK and safety of multiple ascending doses of iv oseltamivir in healthy adults Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0134|cit134","unstructured":"A randomized, double-blind trial evaluating conventional and high dose Tamiflu in the treatment of influenza in immunocompromised patients Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0135|cit135","unstructured":"A double-blind, randomized, placebo controlled multicenter trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0136|cit136","unstructured":"An influenza resistance information study (IRIS) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0137|cit137","unstructured":"A randomized, multicenter trial of oseltamivir [Tamiflu] doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days to evaluate the effect on the duration of viral shedding in influenza patients with pandemic (H1N1) 2009 Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0138|cit138","unstructured":"Avian\/pandemic influenza registry final report, 30 August 2012 Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0139|cit139","unstructured":"A randomized, multicenter, parallel study of the safety, pharmacokinetics and the effect on viral activity of intravenously administered Tamiflu [oseltamivir] in patients with influenza over 13 years of age Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0140|cit140","unstructured":"A prospective, observational safety study in children \u2264 24 months of age receiving oseltamivir for the treatment or prophylaxis of influenza infection Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0141|cit141","unstructured":"An open-label, prospective, single oral dose study evaluating the pharmacokinetics, safety and tolerability of oseltamivir (Tamiflu) in adult subjects on peritoneal dialysis (PD) using a rapid cycle regimen to simulate automated peritoneal dialysis (APD) and in adult subjects with creatinine clearance from 10-30 mL\/min not on dialysis Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0142|cit142","unstructured":"A single oral dose, multi-center, open label study of the pharmacokinetics, safety and tolerability of Ro 04-0796\/GS4104 in ESRD subjects on hemodialysis and peritoneal dialysis Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0143|cit143","unstructured":"An open label study of the pharmacokinetics of oseltamivir (Ro 64-0796) in children aged 0 - 5 years old after a single dose Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0144|cit144","unstructured":"Double-blind, randomized, placebo controlled, single ascending i.v. dose study of the tolerability (with emphasis of nausea and vomiting), safety, pharmacokinetics of oseltamivir (Ro 64-0796) and its active metabolite oseltamivir carboxylate (Ro 64-0802) in healthy male volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0145|cit145","unstructured":"GS97802 - challenge flu A treatment Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0146|cit146","unstructured":"GS-97801 challenge flu A treatment Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0147|cit147","unstructured":"Single ascending oral dose study of the tolerability, safety and pharmacokinetics (including effect of food) of the neuraminidase inhibitor GS4104 in healthy volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0148|cit148","unstructured":"Multiple ascending oral dose study of the tolerability, safety and pharmacokinetics of the neuraminidase inhibitor, GS4104 in healthy volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0149|cit149","unstructured":"Multiple ascending oral dose study of the tolerability, safety and pharmacokinetics of the neuraminidase inhibitor Ro 64-0796 in healthy elderly volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0150|cit150","unstructured":"Multiple oral dose study of the pharmacokinetics, tolerability and safety of the neuraminidase inhibitor Ro 64-0796 in patients with renal impairment Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0151|cit151","unstructured":"Study of the safety and pharmacokinetics of the neuraminidase inhibitor Ro 64-0796 in healthy volunteers when administered concomitantly with paracetamol (acetaminophen) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0152|cit152","unstructured":"An open-label, relative bioavailability study of the phase III pediatric clinical trial and market formulations of Ro 64-0796 in healthy volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0153|cit153","unstructured":"An open-label, three-way crossover, pharmacokinetic drug interaction study of neuraminidase inhibitor Ro 64-0796 and aspirin in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0154|cit154","unstructured":"An open label bioequivalence and food effect study of the enteric coated and immediate release formulations of oseltamivir in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0155|cit155","unstructured":"An open-label, bioequivalence study of the phase III pediatric clinical trial and market oral suspension formulations of Ro 64-0796 in healthy volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0156|cit156","unstructured":"An open-label, relative bioavailability study of the market suspension (with improved process), the clinical trial suspension and market capsule formulation of Ro 64-0796 (Tamiflu, oseltamivir) in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0157|cit157","unstructured":"A study of the pharmacokinetics of oseltamivir (Ro 64-796) and its active metabolite Ro 64-0802 following single oral dosing of Ro 64-0796 to healthy volunteers and patients with moderate hepatic impairment Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0158|cit158","unstructured":"A pharmacokinetic drug interaction study of oseltamivir (Ro 64-0796) and antacid in healthy volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0159|cit159","unstructured":"A randomized, double blind, parallel group, placebo controlled study of the effect of oseltamivir on ECG intervals in healthy subjects Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0160|cit160","unstructured":"A randomized, open label study of the site of absorption of oseltamivir in healthy subjects using an Enterion capsule Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0161|cit161","unstructured":"Clinical pharmacokinetics of cyclosporine or mycophenolate with and without a concurrent single dose of oseltamivir phosphate in patients with a renal transplant Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0162|cit162","unstructured":"Comparison of the pharmacokinetics of Ro 64-0802 following a single dose of oseltamivir phosphate either in a capsule or a drinking solution Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0163|cit163","unstructured":"A combined single ascending dose, multiple ascending dose and exploratory bioavailability study to investigate the safety, tolerability and pharmacokinetics of intravenous Ro\u00a064-0796 in healthy volunteers Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0164|cit164","unstructured":"Oseltamivir treatment for children less than 24 months of age with influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0165|cit165","unstructured":"An open-label, randomized 2-period crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of warfarin, and the pharmacokinetics, safety and tolerability of oseltamivir, when given in combination Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0166|cit166","unstructured":"An open label, prospective, pharmacokinetic\/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu\u00ae) in the treatment of infants 0 to < 12 months of age with confirmed influenza infection Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0167|cit167","unstructured":"A double-blind, randomized, stratified pilot study of Ro 64-0796 (also known as GS4104) in children with influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0168|cit168","unstructured":"(Oseltamivir trial. Title unknown) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0169|cit169","unstructured":"A randomized, open-label, parallel group study of oseltamivir used for management of influenza in households Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10156-013-0622-9","article-title":"Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial","volume":"19","author":"Kashiwagi","year":"2013","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0171|cit171","unstructured":"Economic and social benefits of treating and preventing influenza in aged care facilities Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0172|cit172","unstructured":"A randomized, open label study to evaluate the effect of Tamiflu on viral shedding and on serum and cytoplasmic inflammatory cytokine concentrations in patients with laboratory-confirmed influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0173|cit173","unstructured":"Pilot study to develop a model to evaluate nosocomial transmission of influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0174|cit174","unstructured":"A double-blind, randomized, placebo-controlled study of early oseltamivir treatment of influenza in children 1-3 years of age Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0175|cit175","unstructured":"A phase 4, multi-center, randomized, double blind, placebo controlled study, to evaluate the safety of inhaled zanamivir 10 mg versus placebo and oral oseltamivir 75 mg versus placebo for influenza prophylaxis in healthy volunteers for 16 weeks Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0176|cit176","unstructured":"Efficacy of oseltamivir in reducing the duration of clinical illness, viral shedding, and transmissibility reduction within households among participants in an influenza disease burden surveillance cohort in urban Dhaka, Bangladesh Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0177|cit177","unstructured":"Viral shedding\/resistance with standard dose\/duration oseltamivir in infected patients (South Africa) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0178|cit178","unstructured":"A randomised controlled trial on the effect of post-exposure oseltamivir prophylaxis on influenza transmission in nursing homes (PEPpIE) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0179|cit179","unstructured":"A phase II, multicenter, randomized, double-mask, placebo-controlled study to evaluate the efficacy and safety of intramuscular peramivir in subjects with uncomplicated acute influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0180|cit180","unstructured":"A phase II, multicenter, randomized, double-mask, double-dummy study comparing the efficacy and safety of peramivir administered intravenously once daily versus oseltamivir administered orally twice daily in adults with acute serious or potentially life-threatening influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0181|cit181","unstructured":"A phase 3 multicenter, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of intramuscular peramivir in subjects with uncomplicated acute influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0182|cit182","unstructured":"Monitoring influenza severity and transmission on Tamiflu (MISTT) Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0183|cit183","unstructured":"A phase 3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intramuscular peramivir in subjects with uncomplicated acute influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0184|cit184","unstructured":"A phase II, multicenter, randomized, placebo-controlled, study to evaluate the efficacy and safety of intramuscular peramivir 600 mg in subjects with uncomplicated acute influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0185|cit185","unstructured":"A phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza Data on file"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dks418","article-title":"Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: A randomized, double-blind, placebo-controlled safety trial over 16 weeks","volume":"68","author":"Anekthananon","year":"2013","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1750-2659.2011.00312.x","article-title":"Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial","volume":"6","author":"Dharan","year":"2012","journal-title":"Influenza and Other Respiratory Viruses"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0188|cit188","unstructured":"An open label, multicenter trial of\u00a0oseltamivir prophylaxis of seasonal influenza in children Data on file"},{"issue":"7425","key":"10.1002\/14651858.CD008965.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/bmj.327.7425.1222","article-title":"Joining the DoTS: new approach to classifying adverse drug reactions","volume":"327","author":"Aronson","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD008965.pub4-BIB0190|cit190","first-page":"111","article-title":"How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency (Letter)","volume":"12","author":"Bhatia","year":"2007","journal-title":"Cellular and Molecular Biology"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7326\/0003-4819-153-3-201008030-00006","article-title":"Outcome reporting among drug trials registered in ClinicalTrials.gov","volume":"153","author":"Bourgeois","year":"2010","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0192|cit192","unstructured":"Brown JKM Experimental design generator and randomiser http:\/\/www.edgarweb.org.uk\/"},{"issue":"9","key":"10.1002\/14651858.CD008965.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1473-3099(09)70199-9","article-title":"Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis","volume":"9","author":"Burch","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/jama.293.8.987","article-title":"Does this patient have influenza?","volume":"8","author":"Call","year":"2005","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008965.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"issue":"19","key":"10.1002\/14651858.CD008965.pub4-BIB0196|cit196","first-page":"521","article-title":"Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine","volume":"58","author":"U.S. Centers for Disease Control and Prevention","year":"2009","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"23","key":"10.1002\/14651858.CD008965.pub4-BIB0197|cit197","first-page":"473","article-title":"Influenza activity \u2014 United States, 2012\u201313 season and composition of the 2013\u201314 influenza vaccine","volume":"62","author":"U.S. Centers for Disease Control and Prevention","year":"2013","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD008965.pub4-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.7326\/0003-4819-142-12_Part_2-200506211-00009","article-title":"Challenges in systematic reviews that assess treatment harms","volume":"142","author":"Chou","year":"2005","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008965.pub4-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1302\u20133","DOI":"10.1093\/cid\/cir706","article-title":"Does oseltamivir really reduce complications of influenza?","volume":"53","author":"Cochrane Neuraminidase Inhibitors Review Team","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"b5387","DOI":"10.1136\/bmj.b5387","article-title":"Complications: tracking down the data on oseltamivir","volume":"339","author":"Cohen","year":"2009","journal-title":"BMJ"},{"issue":"7401","key":"10.1002\/14651858.CD008965.pub4-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bmj.326.7401.1235","article-title":"Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials","volume":"326","author":"Cooper","year":"2003","journal-title":"BMJ"},{"issue":"32","key":"10.1002\/14651858.CD008965.pub4-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1016\/S0264-410X(01)00219-5","article-title":"The effect of zanamivir treatment on the early immune response to influenza vaccination","volume":"19","author":"Cox","year":"2001","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"b5164","DOI":"10.1136\/bmj.b5164","article-title":"Neuraminidase inhibitors - the story behind the Cochrane review","volume":"339","author":"Doshi","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD008965.pub4-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"e1001201","DOI":"10.1371\/journal.pmed.1001201","article-title":"The imperative to share clinical study reports: recommendations from the Tamiflu experience","volume":"9","author":"Doshi","year":"2012","journal-title":"PLoS Med"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"d7898","DOI":"10.1136\/bmj.d7898","article-title":"Rethinking credible evidence synthesis","volume":"344","author":"Doshi","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"e002496","DOI":"10.1136\/bmjopen-2012-002496","article-title":"Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports","volume":"3","author":"Doshi","year":"2013","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"461\u20137","DOI":"10.1016\/j.ijantimicag.2009.12.023","article-title":"Safety and pharmacokinetics of oseltamivir at standard and high dosages","volume":"35","author":"Dutkowski","year":"2010","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"2","key":"10.1002\/14651858.CD008965.pub4-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/fampra\/cms059","article-title":"Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials","volume":"30","author":"Ebell","year":"2012","journal-title":"Family Practice"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0209|cit209","unstructured":"European Medicines Agency Annex I. Summary of product characteristics (Tamiflu 30 mg hard capsule) http:\/\/www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500033106 (accessed 21 January 2010)"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0210|cit210","unstructured":"European Agency for the Evaluation of Medicinal Products Tamiflu. Oseltamivir phosphate. (EMEA\/H\/C\/402) CPMP recommendation & scientific discussion consolidated list of questions (June 28, 2001) http:\/\/www.ema.europa.eu\/"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"c4737","DOI":"10.1136\/bmj.c4737","article-title":"Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials","volume":"341","author":"Eyding","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/jac\/dkq158","article-title":"Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0213|cit213","unstructured":"Food Drug Administration Administrative\/correspondence documents part 2. Relenza (Zanamivir). Application No.:\u00a021036 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/021036-admin2.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0214|cit214","unstructured":"Food Drug Administration Medical review part 6. Relenza (zanamivir). Application No.:\u00a021036 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/021036-medreview6.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0215|cit215","unstructured":"Food Drug Administration Tamiflu (Oseltamivir Phosphate) Capsule. Medical Review Part 2 (Application No.:\u00a0021087) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/21087_Tamiflu_medr_P1.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0216|cit216","unstructured":"Food Drug Administration Letter from FDA to Hoffman-La Roche Inc. re \"NDA 21-087 TAMIFLU (oseltamivir phosphate) MACMIS ID#8675 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/EnforcementActivitiesbyFDA\/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies\/UCM166329.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0217|cit217","unstructured":"Food Drug Administration Drug approval package. Relenza (zanamivir). Application No.: 021036S001. Label http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21036S1LBL.PDF"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0218|cit218","unstructured":"Food Drug Administration Drug approval package. Tamiflu (oseltamivir). Application No.: 021087-SE1-002 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21-087SE1-002_review.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0219|cit219","unstructured":"Food Drug Administration Review. Tamiflu (oseltamivir). NDA 021087 Supplement 002 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21-087SE1-002_review.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0220|cit220","unstructured":"Food Drug Administration Site inspection report in Review. Tamiflu (oseltamivir). NDA 021087 Supplement 002 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21-087SE1-002_review.pdf 177"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0221|cit221","unstructured":"Food Drug Administration Faxed letter to Roche (file UCM166329) http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/EnforcementActivitiesbyFDA\/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies\/UCM166329.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0222|cit222","unstructured":"F. Hoffman-La Roche Tamiflu label (for FDA NDA no. 021087) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021087s057lbl.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0223|cit223","unstructured":"Food Drug Administration Drugs@FDA http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0224|cit224","unstructured":"Food Drug Administration Warning letters http:\/\/www.fda.gov\/ICECI\/EnforcementActions\/WarningLetters\/default.htm"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0225|cit225","unstructured":"Feinberg J Wordle http:\/\/www.wordle.net\/"},{"issue":"3","key":"10.1002\/14651858.CD008965.pub4-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3923\/ijv.2009.119.130","article-title":"Oseltamivir is devoid of specific behavioral and other central nervous system effects in juvenile rats at supratherapeutic oral doses","volume":"5","author":"Freichel","year":"2009","journal-title":"International Journal of Virology"},{"issue":"3","key":"10.1002\/14651858.CD008965.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1086\/314938","article-title":"Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment","volume":"180","author":"Fritz","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0228|cit228","first-page":"73","article-title":"A pharmacoepidemiological study on the relationship between neuropsychiatric symptoms and therapeutic drugs after influenza infection","volume":"15","author":"Fujita","year":"2010","journal-title":"Japanese Journal of Pharmacoepidemiology"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0229|cit229","unstructured":"Ghersi D Clarke MJ Reveiz L Do Cochrane reviews search databases of ongoing trials, and how well do they report these searches? Oral presentation at the Joint Cochrane and Campbell Collaboration http:\/\/www.cochrane.org\/sites\/default\/files\/uploads\/abstract_book_keystone_2010.pdf 2010 45 6 10.1002\/14651858"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"b5351","DOI":"10.1136\/bmj.b5351","article-title":"Why don't we have all the evidence on oseltamivir?","volume":"339","author":"Godlee","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0231|cit231","doi-asserted-by":"crossref","unstructured":"Godlee F Loder E Missing clinical trial data: setting the record straight BMJ 2010 c5641","DOI":"10.1136\/bmj.c5641"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0232|cit232","doi-asserted-by":"crossref","unstructured":"Gotzsche PC Jorgensen AW Opening up data at the European Medicines Agency BMJ 2011 d2686","DOI":"10.1136\/bmj.d2686"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/jgs.12250","article-title":"Erratum","volume":"61","author":"Gravenstein","year":"2013","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JRS-2008-0431","article-title":"Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships","volume":"20","author":"Hama","year":"2008","journal-title":"International Journal of Risk and Safety in Medicine"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0235|cit235","unstructured":"Hama R Jones M Hayashi K Yanagi K Sakaguchi K Oseltamivir: a systematic review and meta-analysis of adverse effects in prospective cohort studies Presentation at the 16th Japanese Society for Pharmaco-epidemiology (JSPE) and 5th Activities and Co-operation for Drug Safety in Asia (ACPE) Joint Meeting Tokyo 2010"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3233\/JRS-2011-0545","article-title":"Oseltamivir and early deterioration leading to death","volume":"23","author":"Hama R. Jones","year":"2011","journal-title":"International Journal of Risk & Safety in Medicine"},{"issue":"13","key":"10.1002\/14651858.CD008965.pub4-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"Hayden","year":"1999","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008965.pub4-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold?","volume":"48","author":"Hayden","year":"2009","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008965.pub4-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/cid\/cir400","article-title":"Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials","volume":"53","author":"Hernan","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0240|cit240","unstructured":"U.S. Department of Health and Human Services HHS pandemic influenza plan http:\/\/www.hhs.gov\/pandemicflu\/plan\/pdf\/HHSPandemicInfluenzaPlan.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0241|cit241","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from: http:\/\/www.cochrane-handbook.org"},{"issue":"9","key":"10.1002\/14651858.CD008965.pub4-BIB0242|cit242","doi-asserted-by":"publisher","first-page":"e25258","DOI":"10.1371\/journal.pone.0025258","article-title":"Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy","volume":"6","author":"Huic","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0243|cit243","unstructured":"The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) M4: the common technical document http:\/\/www.ich.org\/products\/ctd.html"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"c4875","DOI":"10.1136\/bmj.c4875","article-title":"The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence","volume":"341","author":"Ioannidis","year":"2010","journal-title":"BMJ"},{"issue":"7258","key":"10.1002\/14651858.CD008965.pub4-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/nature08260","article-title":"In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses","volume":"460","author":"Itoh","year":"2009","journal-title":"Nature"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0246|cit246","unstructured":"Jack A Roche steps up production of Tamiflu after virus scare Financial Times 19"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0247|cit247","unstructured":"Japanese Association for Infectious Diseases Question and answers on the Japanese Association for Infectious Diseases urgent recommendation \"Handling pandemic influenza in routine care institutions\" http:\/\/www.kansensho.or.jp\/topics\/090525influenza_qanda.html"},{"issue":"3","key":"10.1002\/14651858.CD008965.pub4-BIB0248|cit248","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001265.pub2","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults","author":"Jefferson","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"b5106","DOI":"10.1136\/bmj.b5106","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis","volume":"339","author":"Jefferson","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD008965.pub4-BIB0250|cit250","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001265.pub2","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults","author":"Jefferson","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008965.pub4-BIB0251|cit251","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006207.pub4","article-title":"Physical interventions to interrupt or reduce the spread of respiratory viruses","author":"Jefferson","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"c7258","DOI":"10.1136\/bmj.c7258","article-title":"Ensuring safe and effective drugs: who can do what it takes?","volume":"342","author":"Jefferson","year":"2011","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD008965.pub4-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/BF03262007","article-title":"Neuropsychiatric adverse events and oseltamivir for prophylaxis","volume":"35","author":"Jones","year":"2012","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.163.14.1667","article-title":"Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations","volume":"163","author":"Kaiser","year":"2003","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008965.pub4-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1742-7843.2012.00889.x","article-title":"High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats","volume":"111","author":"Kimura","year":"2012","journal-title":"Basic & Clinical Pharmacology & toxicology"},{"issue":"7400","key":"10.1002\/14651858.CD008965.pub4-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD008965.pub4-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/cr.2007.27","article-title":"A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir","volume":"17","author":"Li","year":"2007","journal-title":"Cell Research"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0258|cit258","first-page":"1099","article-title":"Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding","volume":"2","author":"Liu","journal-title":"Journal of Virology"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/aje\/kwh092","article-title":"Containing pandemic influenza with antiviral agents","volume":"159(7)","author":"Longini","year":"2004","journal-title":"Am J Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD008965.pub4-BIB0260|cit260","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008965.pub4-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0895-4356(02)00520-6","article-title":"How useful are unpublished data from the Food and Drug Administration in meta-analysis?","volume":"56","author":"MacLean","year":"2003","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD008965.pub4-BIB0262|cit262","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002744.pub2","article-title":"Neuraminidase inhibitors for preventing and treating influenza in children","author":"Matheson","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"22","key":"10.1002\/14651858.CD008965.pub4-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1128\/JVI.78.22.12665-12667.2004","article-title":"Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium","volume":"78","author":"Matrosovich","year":"2004","journal-title":"Journal of Virology"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0264|cit264","unstructured":"Maugh TH II British Medical Journal questions efficacy of Tamiflu for swine flu - or any flu http:\/\/latimesblogs.latimes.com\/booster_shots\/2009\/12\/british-medical-journal-questions-efficacy-of-tamiflu-for-swine-flu-or-any-flu.html"},{"issue":"1","key":"10.1002\/14651858.CD008965.pub4-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1745-6215-11-37","article-title":"Reporting bias in medical research - a narrative review","volume":"11","author":"McGauran","year":"2010","journal-title":"Trials"},{"issue":"3","key":"10.1002\/14651858.CD008965.pub4-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/AAC.42.3.640","article-title":"Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection","volume":"42","author":"Mendel","year":"1998","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD008965.pub4-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.4049\/jimmunol.178.5.2651","article-title":"Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity","volume":"178","author":"Moore","year":"2007","journal-title":"Journal of Immunology"},{"issue":"13","key":"10.1002\/14651858.CD008965.pub4-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0269|cit269","unstructured":"Nebehay S WHO backs findings on Tamiflu for seasonal flu http:\/\/www.reuters.com\/article\/idUSGEE5BA0UY20091211?type=marketsNews"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0270|cit270","unstructured":"National Health Service NHS choices. Antivirals and swine flu http:\/\/www.nhs.uk\/news\/2009\/12December\/Pages\/Antivirals-and-swine-flu.aspx"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0271|cit271","unstructured":"National Health Service NHS Choices. Swine flu - questions and answers http:\/\/www.nhs.uk\/Conditions\/Pandemic-flu\/Pages\/QA.aspx"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0272|cit272","unstructured":"Roche Tamiflu (oseltamivir phosphate) NICE submission (leaked document)"},{"issue":"9218","key":"10.1002\/14651858.CD008965.pub4-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group","volume":"355","author":"Nicholson","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008965.pub4-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.micinf.2005.12.008","article-title":"Roles of neuraminidase in the initial stage of influenza virus infection","volume":"8","author":"Ohuchi","year":"2006","journal-title":"Microbes and Infection"},{"issue":"4","key":"10.1002\/14651858.CD008965.pub4-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1248\/bpb.31.638","article-title":"Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice","volume":"31","author":"Ono","year":"2008","journal-title":"Biological and Pharmaceutical Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD008965.pub4-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bcpt.12058","article-title":"Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti-influenza virus drug, in normal mice","volume":"113","author":"Ono","year":"2013","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/003335490912400205","article-title":"Does influenza transmission occur from asymptomatic infection or prior to symptom onset?","volume":"124","author":"Patrozou","year":"2009","journal-title":"Public Health Reports"},{"issue":"8","key":"10.1002\/14651858.CD008965.pub4-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1532-5415.2001.49204.x","article-title":"Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population","volume":"49","author":"Peters","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0279|cit279","unstructured":"Roche Investigators Guide http:\/\/www.roche.be\/fmfiles\/re7189007\/CU056\/10_Investigators_brochure.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"f3981","DOI":"10.1136\/bmj.f3981","article-title":"Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion","volume":"346","author":"Rodgers","year":"2013","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD008965.pub4-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1440-1843.2009.01639.x","article-title":"Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza","volume":"14","author":"Sawabuchi","year":"2009","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1002\/sim.2074","article-title":"Added values: controversies concerning randomization and additivity in clinical trials","volume":"23","author":"Senn","year":"2004","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"b3172","DOI":"10.1136\/bmj.b3172","article-title":"Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials","volume":"339","author":"Shun-Shin","year":"2009","journal-title":"BMJ"},{"issue":"9522","key":"10.1002\/14651858.CD008965.pub4-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1571; author re","DOI":"10.1016\/S0140-6736(06)68683-2","article-title":"Antivirals for influenza in healthy adults","volume":"367","author":"Smith","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008965.pub4-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"10","key":"10.1002\/14651858.CD008965.pub4-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.micinf.2010.04.013","article-title":"Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus","volume":"12","author":"Takahashi","year":"2010","journal-title":"Microbes and Infection \/ Institut Pasteur"},{"issue":"iii, ix-xii","key":"10.1002\/14651858.CD008965.pub4-BIB0287|cit287","first-page":"1","article-title":"Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation","volume":"11","author":"Tappenden","year":"2009","journal-title":"Health Technology Assessment"},{"issue":"12","key":"10.1002\/14651858.CD008965.pub4-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2165\/0002018-200831120-00006","article-title":"Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir. A comprehensive review","volume":"31","author":"Toovey","year":"2008","journal-title":"Drug Safety"},{"issue":"12","key":"10.1002\/14651858.CD008965.pub4-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/BF03262008","article-title":"The author's reply","volume":"35","author":"Toovey","year":"2012","journal-title":"Drug Safety"},{"issue":"8","key":"10.1002\/14651858.CD008965.pub4-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"issue":"35","key":"10.1002\/14651858.CD008965.pub4-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"iii-iv, xi-xiii","DOI":"10.3310\/hta7350","article-title":"Systematic review and economic decision modelling for the prevention and treatment of influenza A and B","volume":"7","author":"Turner","year":"2003","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jclinepi.2008.09.010","article-title":"Searching for unpublished trials in Cochrane reviews may not be worth the effort","volume":"62","author":"Driel","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"20","key":"10.1002\/14651858.CD008965.pub4-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"1963\u201371","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry-sponsored trials of gabapentin for off-label use","volume":"361","author":"Vedula","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008965.pub4-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"e1001378","DOI":"10.1371\/journal.pmed.1001378","article-title":"Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin","volume":"10","author":"Vedula","year":"2013","journal-title":"PLoS Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008965.pub4-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dki018","article-title":"Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic","volume":"55","author":"Ward","year":"2005","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"22","key":"10.1002\/14651858.CD008965.pub4-BIB0296|cit296","first-page":"179","article-title":"Global agenda on influenza--adopted version. Part I","volume":"77","author":"World Health Organization","year":"2002","journal-title":"Releve Epidemiologique Hebdomadaire\/Section d'Hygiene du Secretariat de la Societ\u00e9 des Nations = Weekly Epidemiological Record\/Health Section of the Secretariat of the League of Nations"},{"issue":"23","key":"10.1002\/14651858.CD008965.pub4-BIB0297|cit297","first-page":"191","article-title":"Adoption of global agenda on influenza - Part II","volume":"77","author":"World Health Organization","year":"2002","journal-title":"Releve Epidemiologique Hebdomadaire\/Section d'Hygiene du Secretariat de la Societ\u00e9 des Nations = Weekly Epidemiological Record\/Health Section of the Secretariat of the League of Nations"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0298|cit298","unstructured":"World Health Organization WHO guidelines on the use of vaccines and antivirals during influenza pandemics http:\/\/www.who.int\/csr\/resources\/publications\/influenza\/11_29_01_A.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0299|cit299","unstructured":"World Health Organization WHO interim protocol: rapid operations to contain the initial emergence of pandemic influenza http:\/\/www.who.int\/influenza\/resources\/documents\/RapidContProtOct15.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0300|cit300","unstructured":"World Health Organization UNEDITED REPORT of the 18th Expert Committee on the selection and use of essential medicines http:\/\/www.who.int\/entity\/selection_medicines\/Complete_UNEDITED_TRS_18th.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0301|cit301","unstructured":"World Health Organization WHO Model List of Essential Medicines. ADULTS, 18th edition (April 2013). Rev. Oct 2013 http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/18th_EML_Final_web_8Jul13.pdf"},{"key":"10.1002\/14651858.CD008965.pub4-BIB0302|cit302","unstructured":"World Health Organization WHO Model List of Essential Medicines for Children. 4th list (April 2013). Rev. Oct 2013 http:\/\/apps.who.int\/iris\/bitstream\/10665\/93143\/1\/EMLc_4_eng.pdf"},{"issue":"10","key":"10.1002\/14651858.CD008965.pub4-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"e1001526","DOI":"10.1371\/journal.pmed.1001526","article-title":"Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data","volume":"10","author":"Wieseler","year":"2013","journal-title":"PLoS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008965.pub4-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/EDE.0b013e3181a3d3f6","article-title":"Oseltamivir and abnormal behaviors: true or not?","volume":"20","author":"Yorifuji","year":"2009","journal-title":"Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD008965.pub4-BIB0305|cit305","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008965.pub3","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","author":"Jefferson","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008965.pub4\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T19:36:42Z","timestamp":1703014602000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008965.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Acute Respiratory Infections Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,10]]},"references-count":305,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008965.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,10]]}}}